ABBV-466, A NOVEL DUAL-TARGETING THERAPY, LEADS TO ENDOSCOPIC REMISSION IN MODERATE-TO-SEVERE CROHN'S DISEASE: PRIMARY RESULTS AND MOLECULAR PROFILING FROM THE PHASE 2A TARGET-CD STUDY (UEGW 2026) - Sep 24, 2026 - Abstract #LB08; Pres time: Oct 19, 2026; 10:10 AM - 10:20 AM; Location: Room UEG Forum; P2 | "Introduction: Analysis of patients (pts) with Crohn's disease (CD) treated with risankizumab (RZB) in the phase 3 studies who achieved clinical response, yet failed to achieve endoscopic remission, demonstrated a persistent signature of the α4β7 pathway in mucosal biopsies. ABBV-466 is a novel dual-targeting therapy comprising RZB against IL-23 p19 and trosunilimab (TROSU) against α4β7... In pts with moderate-to-severe CD, ABBV-466 therapy demonstrated a higher endoscopic remission rate than either monotherapy at Wk12, which increased through Wk24. This was accompanied by coordinated mechanistic changes indicative of mucosal healing. ABBV-466 was well tolerated with no concerning safety signals."
Clinical • Late-breaking abstract • P2a data • Crohn's disease • Gastroenterology • Immunology • Infectious Disease • Inflammatory Bowel Disease • IL23A
|
|
R. Panaccione 1; S. Danese 2; L. Peyrin-Biroulet 3; J.O. Lindsay 4; B. Verstockt 5; J.-F. Colombel 6; M.C. Dubinsky 6; J. Eccleston 7; I. Messina 7; S. Laroux 8; A. Zimmerman-Bennett 7; M. Liu 7; B. Ravishankar 8; T. Feng 7; R. D'Cunha 7; D.T. Rubin 9
|